• COMPASS and ACANet accepted by Nature Medicine and Nature Communications, respectively.
  • FPPool, a knowledge-guided pooling framework connecting molecular fingerprints and graph neural networks, is on ChemRxiv.
  • Medea, an omics AI agent for automated therapeutic discovery, is posted on bioRxiv.
  • Dr. Shen joins Zhejiang University as Assistant Professor under the Hundred Talents Program.
  • AI Agents for Drug Discovery: Closing the Loop from Hypothesis to Molecule — Drug discovery is slow, expensive, and iterative. AI agents — systems that reason, plan, and use tools autonomously — are poised to close the design–synthesize–test loop at unprecedented speed. We discuss architecture, challenges, and our work on Medea and Leadmaster.
  • FPPool: Bridging Molecular Fingerprints and Graph Neural Networks — We introduce FPPool, a knowledge-guided graph pooling framework that uses chemical fingerprints to decompose molecular graphs into biochemically meaningful substructures. State-of-the-art on 40 benchmarks with built-in interpretability.
  • MolMap: Transforming Molecular Fingerprints into 2D Feature Maps — MolMap converts molecular descriptors into structured 2D feature maps, enabling CNNs to learn spatial patterns in molecular property prediction with state-of-the-art accuracy. Published in Nature Machine Intelligence.
  • COMPASS: Predicting Cancer Immunotherapy Response with Multi-Modal AI — COMPASS is our generalizable AI model for predicting cancer immunotherapy response across cancer types and treatments. Multi-center validated with direct clinical translation.